Jazz Pharmaceuticals, shared on LinkedIn:
“Despite the prevalence of gastroesophageal adenocarcinoma (GEA), its complex nature has contributed to limited treatment options and a poor prognosis.
Amal Melhem-Bertrandt, Vice President and Oncology Therapy Area Head, R/D, sheds light on the significant impact GEA has on patients’ quality of life and the need for continued innovation to improve care outcomes.
We’re exploring biomarker-driven approaches to enable more precise therapies and reshape the standard of care for people impacted by HER2-expressing cancers, like GEA.
Other articles about gastroesophageal adenocarcinoma on OncoDaily.